Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest bought additional shares of Shopify, Intellia Therapeutics, and GeneDX on a day when all three fell sharply, with Shopify down 16%, Intellia down 4%, and GeneDX plunging 49%. Shopify’s selloff followed softer near-term guidance despite 34% revenue growth, while GeneDX cut its 2026 revenue outlook to $475 million-$490 million from $540 million-$555 million earlier this year. Intellia was comparatively resilient, with analysts raising targets on encouraging clinical data.

Analysis

This is a classic “quality support vs. fundamentals mean-reversion” setup: the same names are being sold for different reasons, and that matters for forward returns. SHOP’s drawdown looks more like a guidance reset than a business-model break, so the next leg depends on whether the market can re-anchor to cash flow durability rather than growth deceleration; that typically takes one or two clean quarters, not one beat. By contrast, WGS looks more like an expectations air-pocket: once a company cuts forward revenue this sharply, the burden of proof shifts to the next two reporting cycles, and multiple compression can continue even if the stock stops falling immediately.

The second-order winner here may be patient capital in adjacent healthcare platforms. If WGS is losing momentum in reimbursement-sensitive diagnostics, competitors with better payer mix, stronger reference-lab relationships, or higher test utilization can quietly take share without needing the market to explicitly reward them this quarter. In gene editing, NTLA’s bid is really a bet on clinical optionality: a small improvement in data quality or analyst confidence can re-rate the stock violently because the equity is still trading as if binary trial risk dominates all else.

The contrarian miss is that the selloff may be overdone only in SHOP, not across the basket. SHOP can recover on incremental proof that free cash flow remains structurally high even with slower growth, while WGS needs a genuine inflection in reimbursement or volume mix to avoid a prolonged de-rating. NTLA is the highest convexity name: upside is driven by a few data catalysts, but downside remains very shallowly supported until the market believes commercialization is plausible within 12-24 months.

Key Decisions for Investors

• Long SHOP on a 4-8 week horizon only after the post-earnings gap stabilizes; use a starter position or call spread to express rebound potential while capping downside if guidance sentiment keeps bleeding.
• Avoid catching WGS on day one; wait for 2-3 weeks of post-crash price/volume repair or evidence of stabilized reimbursement metrics before considering a tactical long. Until then, the path of least resistance is lower.
• Pair trade: long NTLA / short a more valuation-sensitive biotech index proxy for 1-3 months to isolate catalyst-driven upside from sector beta. NTLA’s upside is convex if analyst targets keep rising; risk is trial disappointment or financing overhang.
• If already long SHOP, sell upside calls against the position for the next quarter to monetize elevated volatility while preserving core exposure to cash-flow durability.
• For contrarians, consider a small basket short WGS against a long in a higher-quality diagnostics/healthcare platform if you can source one; the trade is about relative reimbursement durability, not absolute sector direction.